Literature DB >> 15645130

Characterization and genetic analysis in the newly established human bile duct cancer cell lines.

Mila Ghosh1, Naoto Koike, Shin-Ichi Tsunoda, Takashi Hirano, Sunil Kaul, Hironobu Kashiwagi, Toru Kawamoto, Nobuhiro Ohkohchi, Kaoru Saijo, Tadao Ohno, Masanao Miwa, Takeshi Todoroki.   

Abstract

Bile duct carcinoma patients generally have a poor prognosis. Understanding this cancer at the biological, genetic, molecular, and cellular level in ways relevant to clinical management is essential for developing effective preventive and therapeutic regimens. However, the currently established bile duct cancer cell lines are still insufficient for the research required to attain such an improved understanding. The aim of this study was to establish and characterize human bile duct cancer cell lines. We examined the growth characteristics and colony-forming ability of the established cell lines in terms of their cell cycle parameters and expression of tumor markers (CEA, CA19-9, MUC-1 and c-kit) and oncogene (c-erbB2) by flow cytometry. Comparative genomic hybridization (CGH) was performed to detect changes in the gene copy numbers. Human origin of the cell lines was confirmed by chromosomal analysis. We have established 3 cell lines and designated them as TGBC-47, TGBC-51, and TBCN-6 and the population doubling times of the three cell lines were 28, 38 and 94 h, respectively. The cells maintained differentiation characteristics of the original tumors. Two cell lines formed colonies in the colony forming assays; all three-cell lines expressed CEA, CA19-9, MUC-1 and c-erbB2 and showed chromosomal aneuploidy. CGH analysis demonstrated gains in various chromosomal regions, including 1q, 5p, 6p, 7q and 8q in two cell lines, and the loss in 17p in three cell lines. These newly established cell lines might serve as useful models for studying the advanced molecular tumor biology of bile duct cancer. Furthermore, they may assist translational research in the development of new effective molecular targeting chemoradiotherapy regimens. These chromosomal aberrations and imbalances provide some starting points for the molecular analysis of genomic regions and genes involved in bile duct carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645130

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Establishment and characterization of HEPFT, a cell line derived from hepatoid carcinoma of the fallopian tube, with special reference to alpha-fetoprotein, lectin affinity and histogenesis.

Authors:  Iwao Ishiwata; Makoto Yasuda; Takashi Hirano; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2007-11       Impact factor: 4.174

Review 2.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

3.  Establishment of a human malignant fibrous mesothelioma cell line and the biological characteristics compared with malignant epithelial mesothelioma cell line.

Authors:  Iwao Ishiwata; Emiko Ishiwata; Takashi Hirano
Journal:  Hum Cell       Date:  2008-08       Impact factor: 4.174

4.  Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient.

Authors:  Giuliana Cavalloni; Caterina Peraldo-Neia; Chiara Varamo; Laura Casorzo; Carmine Dell'Aglio; Paola Bernabei; Giovanna Chiorino; Massimo Aglietta; Francesco Leone
Journal:  Tumour Biol       Date:  2015-10-20

5.  Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines.

Authors:  Yanhua Zhang; Jingfeng Luo; Xue Dong; Fang Yang; Miaofeng Zhang; Juanjuan Zhao; Qiangfeng Wang; Fei Zhou; Jihong Sun; Xiaoming Yang
Journal:  Ann Surg Oncol       Date:  2019-07-29       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.